AR046967A1 - Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion - Google Patents
Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicionInfo
- Publication number
- AR046967A1 AR046967A1 ARP040104790A ARP040104790A AR046967A1 AR 046967 A1 AR046967 A1 AR 046967A1 AR P040104790 A ARP040104790 A AR P040104790A AR P040104790 A ARP040104790 A AR P040104790A AR 046967 A1 AR046967 A1 AR 046967A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- alkyl
- heteroaryl
- arylalkyl
- heterocycloalkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000005160 aryl oxy alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- -1 pyrazolo [1,5-A] pyrimidine compound Chemical class 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de pirazolo[1,5-A]pirimidina caracterizado porque tiene la estructura de formula (1), o una sal, éster, solvato, estereoisomero o profármaco farmacéuticamente aceptable de la misma, en la que: ôlínea punteadaö representa el segundo enlace de un doble enlace opcional; R1 es hidrogeno, alquilo, alquilo sustituido, heteroarilo, heteroarilo sustituido, -NH2, o halogeno; R2 es alquilo, alquilo sustituido, -C(O)NR7R8, arilo, arilo sustituido, ariloxialquilo, ariloxialquilo sustituido, heteroarilalcoxialquilo, heteroarilalcoxialquilo sustituido, heterocicloalquilo, heterocicloalquilo sustituido, arilalquilo, arilalquilo sustituido, heteroarilo, o heteroarilo sustituido, en el que dicho heteroarilo o heteroarilo sustituido se une al anillo de pirimidina vía un enlace carbono-carbono; R3 es nada, hidrogeno, o alquilo; Y es =(CR4)- o -(C=O)-; R4 es hidrogeno, alquilo, alquilo sustituido, tioalquilo, alquilsulfinilo, o alquilsulfonilo; Ar es fenilo, fenilo sustituido con 1 o 2 R5, piridilo o piridinilo sustituido con 1 o 2 R5; R5 en cada ocurrencia es hidroxi, alquilo, alquilo sustituido, alcoxi, alcoxi sustituido, ciano, halogeno, alquilsulfonilo, o alquilsulfinilo; Het es heteroarilo opcionalmente sustituido con 1 o 2 R6; R6 en cada ocurrencia es hidroxi, alquilo, alquilo sustituido, alcoxi, alcoxi sustituido, ciano, o halogeno; y R7 y R8 son independientemente hidrogeno, alquilo, alquilo sustituido, arilo, arilo sustituido, heterociclo, heterociclo sustituido, arilalquilo, arilalquilo sustituido, heterocicloalquilo, o heterocicloalquilo sustituido; o R7 y R8 tomados juntos con el nitrogeno al cual están unidos forman un anillo heterocíclico o un anillo heterocíclico sustituido. Composicion farmacéutica que comprende el compuesto anterior en combinacion con un vehículo o diluyente farmacéuticamente aceptable. Uso del compuesto de pirazolo[1,5-A]pirimidina para preparar dicha composicion farmacéutica de utilidad para tratar un trastorno que manifiesta hipersecrecion de CRF en un mamífero, mediante la administracion al animal de una cantidad eficaz de dicha composicion farmacéutica. Dicho trastorno puede ser: ictus, depresion, trastorno relacionado con la ansiedad, trastorno obsesivo-compulsivo, síndrome del intestino irritable, o anorexia nerviosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53203103P | 2003-12-22 | 2003-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046967A1 true AR046967A1 (es) | 2006-01-04 |
Family
ID=34738733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104790A AR046967A1 (es) | 2003-12-22 | 2004-12-20 | Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7737154B2 (es) |
| EP (1) | EP1697374B1 (es) |
| JP (1) | JP4926720B2 (es) |
| KR (1) | KR20070009537A (es) |
| CN (1) | CN1938309B (es) |
| AR (1) | AR046967A1 (es) |
| AU (1) | AU2004309168B2 (es) |
| BR (1) | BRPI0417943A (es) |
| CA (1) | CA2550948A1 (es) |
| IL (1) | IL176350A0 (es) |
| IS (1) | IS8526A (es) |
| MA (1) | MA29984B1 (es) |
| MY (1) | MY143499A (es) |
| NO (1) | NO20063230L (es) |
| NZ (1) | NZ547990A (es) |
| RU (1) | RU2394035C2 (es) |
| TW (1) | TW200530242A (es) |
| WO (1) | WO2005063755A1 (es) |
| ZA (1) | ZA200604574B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| JP2008517060A (ja) * | 2004-10-19 | 2008-05-22 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよびその製法 |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| US8088779B2 (en) * | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
| AU2007297421B2 (en) | 2006-09-20 | 2012-03-08 | Eli Lilly And Company | Thiazole pyrazolopyrimidines as CRF1 receptor antagonists |
| CA2662000C (en) | 2006-09-20 | 2013-01-08 | Eli Lilly And Company | Thiophene pyrazolopyrimidine compounds |
| KR100854679B1 (ko) * | 2007-02-03 | 2008-08-27 | 김기형 | 심플 서비스 로케이션 프로토콜 네트워크 시스템 및 이를구성하는 에이전트. |
| EP2282998B1 (en) * | 2008-04-21 | 2014-09-10 | Albemarle Corporation | Processes for producing n-alkylpyrazole |
| CN102753527B (zh) * | 2010-02-02 | 2014-12-24 | 诺华股份有限公司 | 用作crf受体拮抗剂的环己基酰胺衍生物 |
| WO2014060381A1 (de) | 2012-10-18 | 2014-04-24 | Bayer Cropscience Ag | Heterocyclische verbindungen als schädlingsbekämpfungsmittel |
| BR112015009751A2 (pt) | 2012-10-31 | 2017-07-11 | Bayer Cropscience Ag | novos compostos heterocíclicos como pesticidas |
| US9856262B2 (en) * | 2014-04-10 | 2018-01-02 | Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. | Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitors |
| CN110996943A (zh) | 2017-08-14 | 2020-04-10 | 云杉生物科学公司 | 促肾上腺皮质激素释放因子受体拮抗剂 |
| KR20230092870A (ko) * | 2020-07-27 | 2023-06-26 | 에스팜 바이오테크 피티와이 엘티디 | 화합물 |
| KR20240023691A (ko) | 2020-08-12 | 2024-02-22 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
| US11708372B2 (en) | 2021-11-19 | 2023-07-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2168237T3 (es) * | 1996-02-07 | 2007-04-01 | Neurocrine Biosciences, Inc. | Pirazolopirimidinas como antagonistas de receptores de crf. |
| PT915880E (pt) | 1996-07-24 | 2007-12-31 | Bristol Myers Squibb Pharma Co | Azol triazinas e pirimidinas |
| US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| US6313124B1 (en) * | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| CN1227554A (zh) | 1996-08-28 | 1999-09-01 | 辉瑞大药厂 | 取代的6,5－杂二环衍生物 |
| CA2291709A1 (en) * | 1997-05-30 | 1998-12-03 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| ATE301657T1 (de) * | 1998-01-28 | 2005-08-15 | Bristol Myers Squibb Pharma Co | Azolo-pyrimidine |
| WO2000059908A2 (en) | 1999-04-06 | 2000-10-12 | Du Pont Pharmaceuticals Company | Pyrazolopyrimidines as crf antagonists |
| CA2379633C (en) | 1999-09-30 | 2006-06-20 | Neurogen Corporation | Amino substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines |
| CO5271670A1 (es) | 1999-10-29 | 2003-04-30 | Pfizer Prod Inc | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas |
| MXPA03009938A (es) | 2001-04-30 | 2005-09-07 | Glaxo Group Ltd | Pirimidinas fusionadas como antagonistas del factor liberador de corticotropina. |
| EP1395591B1 (en) | 2001-06-12 | 2008-06-04 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
| GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
| ES2285409T3 (es) | 2003-01-16 | 2007-11-16 | Sb Pharmco Puerto Rico Inc | Derivados pirrol(2,3-b)piridina sustituidos con heteroarilo como antagonistas del receptor de crf. |
| WO2004087707A1 (en) | 2003-03-31 | 2004-10-14 | Vernalis (Cambridge) Limited | Pyrazolopyrimidine compounds and their use in medicine |
| GB0308208D0 (en) | 2003-04-09 | 2003-05-14 | Glaxo Group Ltd | Chemical compounds |
| US20070021429A1 (en) | 2003-04-09 | 2007-01-25 | Yves St-Denis | Condensed n-heterocyclic compounds and their use as crf receptor antagonists |
| US20070293511A1 (en) | 2003-12-22 | 2007-12-20 | Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation | Crf Receptor Antagonists and Methods |
| DE102004008807A1 (de) | 2004-02-20 | 2005-09-08 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
| JP2008517060A (ja) | 2004-10-19 | 2008-05-22 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよびその製法 |
| US8088779B2 (en) | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
-
2004
- 2004-12-20 CN CN2004800420125A patent/CN1938309B/zh not_active Expired - Fee Related
- 2004-12-20 JP JP2006546391A patent/JP4926720B2/ja not_active Expired - Fee Related
- 2004-12-20 US US10/596,648 patent/US7737154B2/en active Active
- 2004-12-20 KR KR1020067012368A patent/KR20070009537A/ko not_active Ceased
- 2004-12-20 AR ARP040104790A patent/AR046967A1/es not_active Application Discontinuation
- 2004-12-20 RU RU2006126675/04A patent/RU2394035C2/ru not_active IP Right Cessation
- 2004-12-20 TW TW093139578A patent/TW200530242A/zh unknown
- 2004-12-20 CA CA002550948A patent/CA2550948A1/en not_active Abandoned
- 2004-12-20 AU AU2004309168A patent/AU2004309168B2/en not_active Ceased
- 2004-12-20 NZ NZ547990A patent/NZ547990A/en unknown
- 2004-12-20 WO PCT/IB2004/004234 patent/WO2005063755A1/en not_active Ceased
- 2004-12-20 MY MYPI20045253A patent/MY143499A/en unknown
- 2004-12-20 EP EP04820857A patent/EP1697374B1/en not_active Expired - Lifetime
- 2004-12-20 BR BRPI0417943-9A patent/BRPI0417943A/pt not_active Application Discontinuation
-
2006
- 2006-06-05 ZA ZA200604574A patent/ZA200604574B/en unknown
- 2006-06-15 IL IL176350A patent/IL176350A0/en unknown
- 2006-06-27 MA MA29147A patent/MA29984B1/fr unknown
- 2006-07-11 IS IS8526A patent/IS8526A/is unknown
- 2006-07-11 NO NO20063230A patent/NO20063230L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MA29984B1 (fr) | 2008-12-01 |
| CN1938309B (zh) | 2011-11-09 |
| RU2006126675A (ru) | 2008-01-27 |
| IS8526A (is) | 2006-07-11 |
| JP4926720B2 (ja) | 2012-05-09 |
| JP2007515472A (ja) | 2007-06-14 |
| RU2394035C2 (ru) | 2010-07-10 |
| BRPI0417943A (pt) | 2007-04-17 |
| EP1697374B1 (en) | 2012-08-29 |
| AU2004309168B2 (en) | 2009-04-23 |
| WO2005063755A1 (en) | 2005-07-14 |
| EP1697374A1 (en) | 2006-09-06 |
| US7737154B2 (en) | 2010-06-15 |
| US20070287705A1 (en) | 2007-12-13 |
| CA2550948A1 (en) | 2005-07-14 |
| TW200530242A (en) | 2005-09-16 |
| AU2004309168A1 (en) | 2005-07-14 |
| ZA200604574B (en) | 2007-11-28 |
| CN1938309A (zh) | 2007-03-28 |
| IL176350A0 (en) | 2006-10-05 |
| NZ547990A (en) | 2010-04-30 |
| KR20070009537A (ko) | 2007-01-18 |
| MY143499A (en) | 2011-05-31 |
| NO20063230L (no) | 2006-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046967A1 (es) | Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| RU2500680C2 (ru) | Новые замещенные пиридин-2-оны и пиридазин-3-оны | |
| JP2008525417A5 (es) | ||
| AR037243A1 (es) | Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento | |
| PE20221336A1 (es) | Compuestos triciclicos sustituidos | |
| JP5864589B2 (ja) | 細菌トポイソメラーゼｉｉ阻害性２−エチルカルバモイルアミノ−１，３−ベンゾチアゾール−５−イル類 | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| PE20090674A1 (es) | Compuestos multiciclicos | |
| CA2682329A1 (en) | Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists | |
| AR045552A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| PE20080403A1 (es) | Derivados heterociclicos fusionados y metodos de uso | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20080102A1 (es) | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
| PE20090511A1 (es) | Imidazopiridinonas | |
| AR071763A1 (es) | Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos | |
| PE20050951A1 (es) | Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas | |
| AR057769A1 (es) | Pirazolo pirimidinas como inhibidores de map quinasa p38, metodos para utilizarlos y composiciones farmaceuticas | |
| PE20060871A1 (es) | Compuestos de piridazinona | |
| PE20081447A1 (es) | Compuestos y composiciones como inhibidores de la proteina cinasa | |
| AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |